Literature DB >> 17084166

The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.

Hideyuki Akaza1, Shiro Hinotsu, Michiyuki Usami, Osamu Ogawa, Susumu Kagawa, Tadaichi Kitamura, Taiji Tsukamoto, Seiji Naito, Yoshihiko Hirao, Masaru Murai, Hidetoshi Yamanaka, Mikio Namiki.   

Abstract

PURPOSE: We analyzed the outcome of primary androgen depletion therapy, which has gained more attention as a potential therapeutic option in patients with localized or locally advanced prostate cancer as it has been increasingly implemented despite limited data on its therapeutic impact in Japan and the United States.
MATERIALS AND METHODS: We analyzed data from CaPSURE and the Japanese Prostate Cancer study.
RESULTS: In Japan primary androgen depletion therapy has long been the treatment of choice for localized and locally advanced prostate cancer. Based on CaPSURE data the frequency of primary androgen depletion therapy being chosen to treat localized and locally advanced disease is also increasing in clinical practice in the United States. A study of the outcomes of endocrine therapy is currently being performed in Japan by the Japanese Prostate Cancer Study Group.
CONCLUSIONS: It is important to obtain such information about the role of primary androgen depletion therapy for localized and locally advanced prostate cancer from studies of natural history and clinical trials. It is also important to update practical treatment guidelines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17084166     DOI: 10.1016/j.juro.2006.06.070

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Prostate cancer: Bicalutamide dose increase in castration-resistant disease.

Authors:  Fernand Labrie
Journal:  Nat Rev Urol       Date:  2014-12-09       Impact factor: 14.432

2.  Relationship Between Aerobic Fitness, the Serum IGF-1 Profiles of Healthy Young Adult African American Males, and Growth of Prostate Cancer Cells.

Authors:  Rajagopalan Sridhar; Vernon Bond; Jacquelyn Dunmore-Griffith; Valerie M Cousins; Renshu Zhang; Richard M Millis
Journal:  Am J Mens Health       Date:  2016-06-22

3.  Long-term quality of life following primary treatment in men with clinical stage T3 prostate cancer.

Authors:  Shunichi Namiki; Tatsuo Tochigi; Shigeto Ishidoya; Akihiro Ito; Isao Numata; Yoichi Arai
Journal:  Qual Life Res       Date:  2010-07-31       Impact factor: 4.147

4.  Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort.

Authors:  Teruo Inamoto; Haruhito Azuma; Shiro Hinotsu; Taiji Tsukamoto; Mototsugu Oya; Osamu Ogawa; Tadaichi Kitamura; Suzuki Kazuhiro; Seiji Naito; Mikio Namiki; Kazuo Nishimura; Yoshihiko Hirao; Michiyuki Usami; Masaru Murai; Hideyuki Akaza
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-28       Impact factor: 4.553

Review 5.  Blockade of testicular and adrenal androgens in prostate cancer treatment.

Authors:  Fernand Labrie
Journal:  Nat Rev Urol       Date:  2011-01-18       Impact factor: 14.432

6.  The change of prostate cancer treatment in Korea: 5 year analysis of a single institution.

Authors:  Dong Hoon Lee; Ha Bum Jung; Mun Su Chung; Seung Hwan Lee; Byung Ha Chung
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

7.  PSA screening for prostate cancer: why so much controversy?

Authors:  Fernand Labrie
Journal:  Asian J Androl       Date:  2013-06-17       Impact factor: 3.285

8.  Current trends in diagnostic and therapeutic principles for prostate cancer in Japan.

Authors:  Koji Okihara; Takumi Shiraishi; Osamu Ukimura; Yoichi Mizutani; Akihiro Kawauchi; Tsuneharu Miki
Journal:  Int J Clin Oncol       Date:  2008-06-14       Impact factor: 3.402

9.  Quality of life among elderly men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.

Authors:  Shunichi Namiki; Shigeto Ishidoya; Sadafumu Kawamura; Tatsuo Tochigi; Yoichi Arai
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-02       Impact factor: 4.553

10.  The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-Oncological Research Group registration.

Authors:  Nobumichi Tanaka; Kiyohide Fujimoto; Akihide Hirayama; Shoji Samma; Hitoshi Momose; Yoshiteru Kaneko; Masaki Haramoto; Yoshiki Hayashi; Yoshinori Nakagawa; Takeshi Otani; Shuji Watanabe; Yoshihiko Hirao
Journal:  BMC Urol       Date:  2011-04-27       Impact factor: 2.264

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.